Back to today’s briefing

Story perspectives

Immunotherapy Boosts Bladder Cancer Survival Rates Dramatically

1/13/2025

29 3

Summary

Story summary

A groundbreaking study of 1,063 bladder cancer patients shows that the immunotherapy drug durvalumab dramatically boosts survival rates and curbs cancer recurrence. After two years, 82.2% of patients on durvalumab were alive, compared to just 75.2% on standard chemotherapy. Experts are optimistic that this life-saving treatment will soon be accessible through the NHS.

1 of 1

Story summary

A groundbreaking study of 1,063 bladder cancer patients shows that the immunotherapy drug durvalumab dramatically boosts survival rates and curbs cancer recurrence. After two years, 82.2% of patients on durvalumab were alive, compared to just 75.2% on standard chemotherapy. Experts are optimistic that this life-saving treatment will soon be accessible through the NHS.